WD-40 shares climb after earnings top estimates, Iovance stock slumps on offering, and other stocks on the moveMarket Watch • 07/11/23
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common StockGlobeNewsWire • 07/11/23
Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common StockGlobeNewsWire • 07/10/23
Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung CancerGlobeNewsWire • 07/10/23
Iovance Biotherapeutics to Host Virtual Roundtable with Key Opinion Leaders to Discuss Melanoma Treatment LandscapeGlobeNewsWire • 06/20/23
Iovance Biotherapeutics Announces First Patient Randomized in Phase 3 TILVANCE-301 Trial in Frontline Advanced MelanomaGlobeNewsWire • 06/15/23
Why Is Iovance Biotherapeutics (IOVA) Up 7.9% Since Last Earnings Report?Zacks Investment Research • 06/08/23
Iovance Biotherapeutics shares rally on receiving FDA priority review for melanoma drugProactive Investors • 05/30/23
Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced MelanomaGlobeNewsWire • 05/26/23
Iovance Biotherapeutics Reports First Quarter 2023 Financial Results and Corporate UpdatesGlobeNewsWire • 05/09/23
Iovance Biotherapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, May 9, 2023GlobeNewsWire • 05/02/23
Iovance Progresses Despite Challenges In Developing Potency Assays For LifileucelSeeking Alpha • 04/23/23